Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT06241066 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma

Start date: January 1, 2014
Phase:
Study type: Observational

Retrospective analysis of the presence and maturity of tertiary lymphoid structures in pathological sections of patients with esophageal squamous cell carcinoma after surgical treatment. Pay attention to the overall survival and disease free survival of these esophageal squamous cell carcinoma patients.

NCT ID: NCT06239727 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication compared with conventional-dose radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage III NPC patients screened out according to the treatment response.

NCT ID: NCT06239220 Recruiting - Clinical trials for Head and Neck Cancer

PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Start date: February 16, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), N-803 (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody) in treating advanced head and neck cancer. The names of the therapies involved in this study are: - PD-L1 t-haNK cell therapy (a NK cell therapy infusion) - N-803 (a type of recombinant human superagonist) - Cetuximab (a type of antibody)

NCT ID: NCT06238635 Recruiting - Cervical Cancer Clinical Trials

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Start date: March 11, 2024
Phase: Phase 2
Study type: Interventional

This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.

NCT ID: NCT06237946 Not yet recruiting - Clinical trials for FIGO Stage IC2 to II Ovarian Clear Cell Carcinoma

Early-stage Ovarian Clear Cell Carcinoma (OCCC) Patients at Risk of Recurrence

Start date: March 15, 2024
Phase:
Study type: Observational

The goal of this observational study is to determine the risk of recurrence in early-stage OCCC (Ovarian Clear Cell Carcinoma) patients who received postoperative adjuvant treatment. Participants were received platinum-based adjuvant therapy following debulking surgery will be included for the study.

NCT ID: NCT06237582 Completed - Clinical trials for Carcinomatosis, Peritoneal

Inferior Epigastric Lymp Node (IELN) Basin as a Possible Systemic Metastatic Pathway of Ovarian Peritoneal Metastases

OvEpiLyPath
Start date: June 16, 2022
Phase: N/A
Study type: Interventional

The IELN basin could represent a primary LN relay for systemic metastatic dissemination in patients with OPM. This newly described lymphatic pathway of metastatic dissemination of OPM may be involved in certain presentations of peritoneal dissemination. The presence of invaded IELN may represent a new biomarker predictive of the pattern of progression of OPM and a related risk for systemic dissemination.

NCT ID: NCT06236464 Recruiting - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas

Start date: September 25, 2023
Phase:
Study type: Observational

This is a multicentric, retrospective, and prospective biomarker study.

NCT ID: NCT06236425 Recruiting - Clinical trials for Squamous Cell Carcinoma of Head and Neck

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Start date: February 5, 2024
Phase: Phase 1
Study type: Interventional

Phase 1b open-label study to evaluate the safety of selected TIL (TBio-4101) delivered after lymphodepleting chemotherapy and followed by intravenous (IV) bolus aldesleukin (IL-2) and pembrolizumab for patients with advanced HNSCC who have initially progressed on pembrolizumab or pembrolizumab/platinum chemotherapy.

NCT ID: NCT06235918 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinomas

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Start date: January 1, 2023
Phase: Phase 2
Study type: Interventional

For resectable squamous cell carcinoma of the head and neck , novel therapeutic approaches are still needed to improve outcomes. Neoadjuvant immunochemotherapy is considered as a potentially effective strategy. The purpose of this study is to evaluate the safety and efficacy of neoadjuvant of tislelizumab combined with platinum doublet for resectable locally-advanced head and neck squamous-cell carcinoma .

NCT ID: NCT06235268 Recruiting - Clinical trials for Carcinoma, Urothelial

Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma

Start date: November 23, 2023
Phase:
Study type: Observational [Patient Registry]

Prospective and multicenter Italian registry intended for naïve adult patients affected by locally advanced-metastatic urothelial carcinoma intended for systemic treatment, or for palliative or observation procedures